SG11202002174SA - Human cytomegalovirus immunogenic composition - Google Patents
Human cytomegalovirus immunogenic compositionInfo
- Publication number
- SG11202002174SA SG11202002174SA SG11202002174SA SG11202002174SA SG11202002174SA SG 11202002174S A SG11202002174S A SG 11202002174SA SG 11202002174S A SG11202002174S A SG 11202002174SA SG 11202002174S A SG11202002174S A SG 11202002174SA SG 11202002174S A SG11202002174S A SG 11202002174SA
- Authority
- SG
- Singapore
- Prior art keywords
- immunogenic composition
- human cytomegalovirus
- cytomegalovirus immunogenic
- human
- composition
- Prior art date
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17306179 | 2017-09-13 | ||
| PCT/EP2018/074369 WO2019052975A1 (en) | 2017-09-13 | 2018-09-11 | IMMUNOGENIC COMPOSITION AGAINST HUMAN CYTOMEGALOVIRUS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002174SA true SG11202002174SA (en) | 2020-04-29 |
Family
ID=60782111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002174SA SG11202002174SA (en) | 2017-09-13 | 2018-09-11 | Human cytomegalovirus immunogenic composition |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US11524069B2 (https=) |
| EP (1) | EP3681534A1 (https=) |
| JP (2) | JP7770767B2 (https=) |
| KR (2) | KR20200051778A (https=) |
| CN (1) | CN111344009A (https=) |
| AU (1) | AU2018331874B2 (https=) |
| BR (1) | BR112020004747A2 (https=) |
| IL (1) | IL273120B2 (https=) |
| MX (1) | MX2020002810A (https=) |
| SG (1) | SG11202002174SA (https=) |
| WO (1) | WO2019052975A1 (https=) |
| ZA (1) | ZA202001561B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11524069B2 (en) | 2017-09-13 | 2022-12-13 | Sanofi Pasteur | Human cytomegalovirus immunogenic composition |
| CA3121915C (en) * | 2018-12-10 | 2025-05-20 | Km Biologics Co., Ltd. | VACCINE FOR THE PREVENTION OR TREATMENT OF CONGENITAL CYTOMEGALOVIRUS INFECTION |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
| AU2021367917A1 (en) * | 2020-10-28 | 2023-06-22 | Sanofi Pasteur | Liposomes containing tlr4 agonist, preparation and uses thereof |
| WO2024218752A1 (en) * | 2023-04-21 | 2024-10-24 | Instar Technologies A.S. | Pharmaceutical composition for vaccination against cytomegalovirus infections |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4987237A (en) | 1983-08-26 | 1991-01-22 | Ribi Immunochem Research, Inc. | Derivatives of monophosphoryl lipid A |
| US6100064A (en) | 1984-04-06 | 2000-08-08 | Chiron Corporation | Secreted viral proteins useful for vaccines and diagnostics |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5547834A (en) | 1988-01-29 | 1996-08-20 | Chiron Corporation | Recombinant CMV neutralizing proteins |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| EP0388186A1 (en) | 1989-03-17 | 1990-09-19 | E.I. Du Pont De Nemours And Company | External regulation of gene expression |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| CA2138997C (en) | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| US5362865A (en) | 1993-09-02 | 1994-11-08 | Monsanto Company | Enhanced expression in plants using non-translated leader sequences |
| US5693506A (en) | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
| US20020102562A1 (en) | 1995-05-24 | 2002-08-01 | Pasteur Merieux Serums Et Vaccines S.A. | Recombinant CMV neutralizing proteins |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6835721B2 (en) | 1999-02-01 | 2004-12-28 | Eisai Co., Ltd. | Immunomodulatory compounds and methods of use thereof |
| US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
| GB0023008D0 (en) | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
| EP2263687B1 (en) | 2002-12-27 | 2015-03-25 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions containing phospholipid |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| EP3031469B1 (en) * | 2006-06-07 | 2023-08-23 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| WO2009037359A1 (en) * | 2007-09-21 | 2009-03-26 | Sanofi Pasteur | Vaccine composition for the prevention of cmv infections |
| CN101959527B (zh) | 2008-03-05 | 2016-04-20 | 赛诺菲巴斯德有限公司 | 一种使含佐剂的疫苗组合物稳定的方法 |
| CA2764374C (en) | 2009-06-05 | 2019-11-19 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
| WO2012051211A2 (en) * | 2010-10-11 | 2012-04-19 | Novartis Ag | Antigen delivery platforms |
| EP2627352B1 (en) | 2010-10-15 | 2017-05-10 | GlaxoSmithKline Biologicals S.A. | Cytomegalovirus gb antigen |
| EA027236B1 (ru) * | 2011-04-08 | 2017-07-31 | Иммьюн Дизайн Корп. | Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа |
| CA2841047A1 (en) * | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
| CA2878344A1 (en) * | 2012-07-06 | 2014-01-09 | Novartis Ag | Complexes of cytomegalovirus proteins |
| CN110241137A (zh) | 2012-07-27 | 2019-09-17 | 希望之城 | 一种递送ul128复合体和预防cmv感染的mva疫苗 |
| CA2885145A1 (en) * | 2012-10-30 | 2014-05-08 | Redvax Gmbh | Recombinant particle based vaccines against human cytomegalovirus infection |
| AU2015251221A1 (en) * | 2014-04-23 | 2016-10-27 | CARIPLO, Fondazione | Human cytomegalovirus vaccine compositions and method of producing the same |
| MX2016014660A (es) * | 2014-05-08 | 2017-02-28 | Pfizer | Medios y metodos para el tratamiento de cmv. |
| EP3031822A1 (en) | 2014-12-08 | 2016-06-15 | Novartis AG | Cytomegalovirus antigens |
| WO2017044895A2 (en) * | 2015-09-10 | 2017-03-16 | City Of Hope | MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF |
| AU2016342045A1 (en) * | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| BR112018076015A8 (pt) * | 2016-06-17 | 2022-06-28 | Sanofi Pasteur | Formulações imunogênicas compreendendo adjuvantes de polímero do ácido poliacrílico linear ou ramificado . |
| US11524069B2 (en) | 2017-09-13 | 2022-12-13 | Sanofi Pasteur | Human cytomegalovirus immunogenic composition |
-
2018
- 2018-09-11 US US16/646,894 patent/US11524069B2/en active Active
- 2018-09-11 MX MX2020002810A patent/MX2020002810A/es unknown
- 2018-09-11 KR KR1020207010481A patent/KR20200051778A/ko not_active Ceased
- 2018-09-11 BR BR112020004747-3A patent/BR112020004747A2/pt not_active Application Discontinuation
- 2018-09-11 WO PCT/EP2018/074369 patent/WO2019052975A1/en not_active Ceased
- 2018-09-11 JP JP2020514916A patent/JP7770767B2/ja active Active
- 2018-09-11 KR KR1020247040905A patent/KR20250006307A/ko active Pending
- 2018-09-11 AU AU2018331874A patent/AU2018331874B2/en active Active
- 2018-09-11 IL IL273120A patent/IL273120B2/en unknown
- 2018-09-11 SG SG11202002174SA patent/SG11202002174SA/en unknown
- 2018-09-11 EP EP18765127.8A patent/EP3681534A1/en active Pending
- 2018-09-11 CN CN201880072392.9A patent/CN111344009A/zh active Pending
-
2020
- 2020-03-12 ZA ZA2020/01561A patent/ZA202001561B/en unknown
- 2020-10-15 US US17/071,817 patent/US11207403B2/en active Active
-
2022
- 2022-12-08 US US18/077,713 patent/US20230277655A1/en active Pending
-
2023
- 2023-11-24 JP JP2023198785A patent/JP2024026160A/ja active Pending
-
2025
- 2025-01-14 US US19/020,003 patent/US20250228933A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020002810A (es) | 2020-07-21 |
| RU2020113253A (ru) | 2021-10-18 |
| KR20200051778A (ko) | 2020-05-13 |
| AU2018331874A1 (en) | 2020-04-30 |
| RU2020113253A3 (https=) | 2021-11-17 |
| JP2024026160A (ja) | 2024-02-28 |
| JP2020533354A (ja) | 2020-11-19 |
| US20250228933A1 (en) | 2025-07-17 |
| BR112020004747A2 (pt) | 2020-09-24 |
| EP3681534A1 (en) | 2020-07-22 |
| IL273120B1 (en) | 2023-06-01 |
| JP7770767B2 (ja) | 2025-11-17 |
| WO2019052975A1 (en) | 2019-03-21 |
| ZA202001561B (en) | 2021-07-28 |
| US20200276301A1 (en) | 2020-09-03 |
| NZ763438A (en) | 2025-03-28 |
| WO2019052975A9 (en) | 2020-04-09 |
| KR20250006307A (ko) | 2025-01-10 |
| CA3075207A1 (en) | 2019-03-21 |
| US20210023202A1 (en) | 2021-01-28 |
| IL273120A (en) | 2020-04-30 |
| US11207403B2 (en) | 2021-12-28 |
| CN111344009A (zh) | 2020-06-26 |
| US11524069B2 (en) | 2022-12-13 |
| US20230277655A1 (en) | 2023-09-07 |
| AU2018331874B2 (en) | 2022-06-02 |
| IL273120B2 (en) | 2023-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273541A (en) | formulations | |
| IL273282A (en) | Niraprib formulations | |
| IL269630A (en) | Niraprib formulations | |
| IL269621A (en) | Niraparib formulations | |
| GB201711635D0 (en) | Immunogenic composition | |
| ZA202001561B (en) | Human cytomegalovirus immunogenic composition | |
| GB201610599D0 (en) | Immunogenic Composition | |
| IL271603A (en) | Immunogenic preparations | |
| GB201707189D0 (en) | Novel formulations | |
| GB201802339D0 (en) | Immunogenic composition | |
| GB201707188D0 (en) | Novel formulations | |
| EP3397277C0 (en) | IMMUNOGENIC COMPOSITION | |
| GB201711637D0 (en) | Immunogenic composition | |
| GB2562241B (en) | Vaccine compositions | |
| GB201707187D0 (en) | Novel formulations | |
| GB201614485D0 (en) | Immunogenic composition | |
| GB201604755D0 (en) | Immunogenic compositions | |
| GB201703529D0 (en) | Vaccine composition | |
| GB201803692D0 (en) | Immunogenic composition | |
| GB201718251D0 (en) | Vaccine Compositions | |
| GB201911959D0 (en) | Immunogenic compositions and uses therefor | |
| HK40034236A (zh) | 人巨细胞病毒免疫原性组合物 | |
| GB201805338D0 (en) | Cosmetic formulations | |
| SG11202004167XA (en) | Immunogenic compositions and uses therefor | |
| GB201820010D0 (en) | Immunogenic composition |